All In MedTech

Device Trial Radar · NCT04295811

Efficacy of EsoGuard Assay on Esophageal Surface Cells Collected With EsoCheck vs EGD for the Diagnosis of BE or EAC

A Multicenter Case-Control Study of the Efficacy of EsoGuard on Samples Collected Using EsoCheck, Versus Esophagogastroduodenoscopy, for the Diagnosis of Barrett's Esophagus With and Without Dysplasia, and for Esophageal Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

784

Actual

Start

Jun 18, 2020

Primary completion

Jun 1, 2027

Study completion Jun 1, 2027

Sponsor

Lead sponsor
Lucid Diagnostics, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 5, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
Male only, from 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study will assess the performance of the combined system, i.e., the use of the EsoGuard assay (lab developed test) on cells collected using the EsoCheck (501k cleared device) to detect Barrett's Esophagus (BE), with or without dysplasia, and esophageal adenocarcinoma (EAC) as compared to Esophagogastroduodenoscopy (EGD) plus biopsies in both confirmed cases of BE/EAC and in controls (subjects without a prior diagnosis but undergoing screening for BE/EAC)

Conditions

  • Barrett Esophagus
  • Esophageal Adenocarcinoma
  • Barretts Esophagus With Dysplasia
  • Barrett's Esophagus Without Dysplasia

Interventions

  • EsoGuard (lab assay)Device

    EsoGuard assay (LDT) will be used on cells collected using the EsoCheck (510K cleared esophageal cell collection device)

  • EsophagogastroduodenoscopyDiagnostic test

    Planned EGD to diagnose and/or treat disorders of esophagus, stomach, and small intestine. When abnormal tissues are noted, biopsies of the tissue are taken through the scope to diagnose tissue abnormalities.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EfficacyTime frame: Per subject analysis through study completion which is up to approximately 5 weeks

Locations

35 sites in 2 countries. Site status is shown where the registry gives one.

  • Lucid Investigative Site

    Aurora, Colorado

  • Lucid Investigative Site

    Englewood, Colorado

  • Lucid Investigative Site

    Washington D.C., District of Columbia

32 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.